Patients with EGFR-expressing tumours had significantly higher response rate (RR) in the BR.21 (P=0.03) and ISEL trials (8.2 vs 1.5% P not reported; Tsao et al, 2005; Hirsch et al, 2006). Here, EGFR is linked to neoplasm.